NCT07892274
Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer
StatusNot Yet Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Progression-Free Survival (PFS)
Timeframe: 24 months
Secondary (7)
Overall Survival (OS)
Objective response rate (ORR)
Clinical Benefit Rate (CBR)
FACT-B
QLQ-BR23
Show 2 moreShow less
Incidence of adverse events(AE)
Biomarkers and treatment sensitivity analysis
Arms and interventions
Fulvestrant + Pyrotinib + DalpiciclibExperimental
Trastuzumab RezetecanActive comparator
Drugs: Fulvestrant, Pyrotinib, Dalpiciclib, Trastuzumab Rezetecan
Sites
1 site in 1 country
- Sun Yat-sen Memorial Hospital, Sun Yat-sen UniversityGuangzhou, Guangdong, China